We extended the above TD findings by counting pPKRThr446-positive immunoreactive cells in the whole thalamus and in specific nuclei in the SmTN and VLN known to be more strongly affected by TD (Figures 2c and d) in animals pretreated (30 mg/kg per os) or not with a PKR inhibitor (PKRinh) provided by Sanofi. This evidence concerns the gene EIF2AK2 and thanatophoric dysplasia.